A CLINICAL TRIAL TO STUDY THE EFFECT OF TRYUSHANADI GUGGULU AND NAVAKA GUGGULU IN THE PATIENTS HAVING SIGN AND SYMPTOMS OF MEDOROGA (ADIPOSOPATHY)

â??PRAKRITI- A RISK FACTOR FOR MEDO ROGA (ADIPOSOPATHY): WHO STEPS BASED NIDANATMAKA STUDY AND RANDOMIZED UPASHAYATMAKA (CLINICAL) TRIAL OF TRYUSHANADI GUGGULU AND NAVAKA GUGGULUâ??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016123

Enrollment

Registered

2018-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified Health Condition 2: E668- Other obesity

Interventions

Intervention1: TRYUSHANADI GUGGULU: CONTENTS-Shunthi(Zingiber officinale),Maricha(Piper nigrum),Pippali(Piper longum),Chitraka(Plumbago zeylanica),Musta(Cyperus rotundus),Vidanga(Embelia ribs),Vacha(A

Eligibility

Inclusion criteria

Inclusion criteria: 1-SUBJECTS OF AGE 18 - 60 YEARS. 2-SUBJECTS OF EITHER SEX. 3-SUBJECTS FOUND TO BE SUFFERING WITH MEDOROGA IN THE NIDANATMAKA STUDY ON THE BASIS OF PARAMETERS SUCH AS ADIPOSOPATHY & DYSLIPIDEMIA AS WELL AS THE AYURVEDIC PARAMETERS AND THEREAFTER CONSENTING TO PARTICIPATE IN THE DRUG TRIAL AND NOT FALLING IN THE EXCLUSION CRITERIA WILL BE INCLUDED

Exclusion criteria

Exclusion criteria: 1-Patients having diabetes mellitus, malignant hypertension and other malignant disorders. 2-Patient having Hypersensitivity, anorexia nervosa, history of Coronary artery disease, Congestive heart failure (CHF), arrhythmias, stroke, cardiac disorders, and those receiving Mono amino oxidase inhibitors (MAOIs ) etc. 3-Pregnant and lactating mothers. 4-Patients having any hormonal disturbances like hypothyroidism. 5-Patients not complying with the directions of the physician. 6-BMI > 40 kg/m2 7-Patient with major complications and in requirement of emergency treatment.

Design outcomes

Primary

Measure	Time frame
patients of both sexes between age group 18 to 60 years of medoroga will be selected for relieving sign and symptomsTimepoint: 4 weeks.	—

Secondary

Measure	Time frame
Asses the comparative efficacy between Tryushanadi Guggulu and Navaka Guggulu in case of medoroga.Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDR PAWAN KUMAR GODATWAR

NATIONAL INSTITUTE OF AYURVEDA,JAIPUR

gpawankumar@rediffmail.com9314502834

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026